Pfizer and Dewpoint Partner for Rare Muscle Disorder Therapeutics

Pfizer and Dewpoint Therapeutics are teaming up to develop potential therapeutics for myotonic dystrophy type 1 (DM1), a form of muscular dystrophy.

The rare genetic disease, known as Steinert disease, is one of two types of myotonic dystrophy and causes progressive muscle weakness and wasting beginning in a patient’s 20s or 30s.

Under the arrangement, Dewpoint will receive an upfront payment and potential future milestone payments totaling $239 million, plus royalties from any approved products.